Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain
- PMID: 8875929
- DOI: 10.1126/science.274.5289.948
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain
Abstract
The MDM2 oncoprotein is a cellular inhibitor of the p53 tumor suppressor in that it can bind the transactivation domain of p53 and downregulate its ability to activate transcription. In certain cancers, MDM2 amplification is a common event and contributes to the inactivation of p53. The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix. The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft. These same p53 residues are also involved in transactivation, supporting the hypothesis that MDM2 inactivates p53 by concealing its transactivation domain. The structure also suggests that the amphipathic alpha helix may be a common structural motif in the binding of a diverse family of transactivation factors to the TATA-binding protein-associated factors.
Comment on
-
Filling in the blanks in the p53 protein structure.Science. 1996 Nov 8;274(5289):921-2. doi: 10.1126/science.274.5289.921. Science. 1996. PMID: 8966571 No abstract available.
Similar articles
-
Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.Cell Cycle. 2008 Aug;7(15):2441-3. doi: 10.4161/cc.6365. Epub 2008 May 27. Cell Cycle. 2008. PMID: 18677113
-
Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.Anticancer Drugs. 2017 Oct;28(9):1032-1038. doi: 10.1097/CAD.0000000000000548. Anticancer Drugs. 2017. PMID: 28723868
-
Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.J Mol Biol. 2005 Jul 15;350(3):587-98. doi: 10.1016/j.jmb.2005.05.010. J Mol Biol. 2005. PMID: 15953616
-
P53 mdm2 inhibitors.Curr Pharm Des. 2012;18(30):4668-78. doi: 10.2174/138161212802651580. Curr Pharm Des. 2012. PMID: 22650254 Free PMC article. Review.
-
A closer view of an oncoprotein-tumor suppressor interaction.Chem Biol. 1997 Nov;4(11):791-4. doi: 10.1016/s1074-5521(97)90112-5. Chem Biol. 1997. PMID: 9384532 Review.
Cited by
-
The Mediator complex subunit MED25 is targeted by the N-terminal transactivation domain of the PEA3 group members.Nucleic Acids Res. 2013 May;41(9):4847-59. doi: 10.1093/nar/gkt199. Epub 2013 Mar 26. Nucleic Acids Res. 2013. PMID: 23531547 Free PMC article.
-
Towards more drug-like proteomimetics: two-faced, synthetic α-helix mimetics based on a purine scaffold.Org Biomol Chem. 2015 Aug 28;13(32):8642-6. doi: 10.1039/c5ob00478k. Epub 2015 Jul 24. Org Biomol Chem. 2015. PMID: 26204921 Free PMC article.
-
Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?Cold Spring Harb Perspect Biol. 2016 Oct 3;8(10):a023614. doi: 10.1101/cshperspect.a023614. Cold Spring Harb Perspect Biol. 2016. PMID: 27549118 Free PMC article. Review.
-
Structure of human MDM2 complexed with RPL11 reveals the molecular basis of p53 activation.Genes Dev. 2015 Jul 15;29(14):1524-34. doi: 10.1101/gad.261792.115. Genes Dev. 2015. PMID: 26220995 Free PMC article.
-
Elucidation of Ligand-Dependent Modulation of Disorder-Order Transitions in the Oncoprotein MDM2.PLoS Comput Biol. 2015 Jun 5;11(6):e1004282. doi: 10.1371/journal.pcbi.1004282. eCollection 2015 Jun. PLoS Comput Biol. 2015. PMID: 26046940 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous